Japan Tissue Engineering (7774) · RiskRestated
Risk of production stoppage due to the inability to procure irreplaceable raw materials and supplies
First written in FY2022. 1 of 2 entries say "Restated". Latest entry: FY2024.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Difficulty continuing production due to raw material supply disruptionsA theme 16 companies write about · 16 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2018: 6 of 10 companies on the "Worse" side.
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 16 companies compared. The sentences above are computed from all 16.Full recordFilings, disclosures and news, newest first
- FY2024RestatedAnnual report
「Because the company uses a certain number of raw materials and other supplies that cannot readily be replaced, production of its own products and products manufactured under contract could be suspended if these materials cannot be procured.」
The company continues to disclose the risk of production stoppages due to the inability to procure difficult-to-substitute raw materials and supplies, with stable supply agreements and consideration of alternative products and technologies as countermeasures. - FY2022First statedAnnual report
「Because the company uses a certain number of raw materials and other supplies that cannot readily be replaced, production of its own products and products manufactured under contract could be suspended if these materials cannot be procured.」
The company identified as a new major risk the possibility that production of its own products and contract-manufactured products could be suspended if difficult-to-substitute raw materials and supplies cannot be procured.